Most serious adverse reactions in patients with ITP include intravascular hemolysis, anemia, acute renal insufficiency, and death. In patients treated for Rh isoimmunization suppression, common adverse effects include nausea, dizziness, headache, pain at injection site and malaise. Common adverse effects in patients with ITP include chills, pyrexia, mild extravascular hemolysis and headache.
Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the Rh0 (D) antigen (D antigen) under the name Rhophylac (IM/IV). Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human plasma, where the donors are Rho (D)-negative donors who have been immunized with Rho(D)-positive RBCs. It was approved by FDA as treatment for suppression of rhesus (Rh) isoimmunization or chronic immune thrombocytopenic purpura (ITP) in adults.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estrone | Estrone may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Mestranol | Mestranol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estriol | Estriol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Tibolone | Tibolone may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Zeranol | Zeranol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Equol | Equol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Promestriene | Promestriene may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Formononetin | Formononetin may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Human Rho(D) immune globulin. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Human Rho(D) immune globulin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Human Rho(D) immune globulin. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Human Rho(D) immune globulin. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Human Rho(D) immune globulin. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Human Rho(D) immune globulin. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Human Rho(D) immune globulin. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Human Rho(D) immune globulin. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Human Rho(D) immune globulin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Human Rho(D) immune globulin. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Human Rho(D) immune globulin. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Human Rho(D) immune globulin. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Human Rho(D) immune globulin. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Human Rho(D) immune globulin. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Human Rho(D) immune globulin. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Human Rho(D) immune globulin. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Human Rho(D) immune globulin. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Human Rho(D) immune globulin. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Human Rho(D) immune globulin. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Human Rho(D) immune globulin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Human Rho(D) immune globulin. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Human Rho(D) immune globulin. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Human Rho(D) immune globulin. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Human Rho(D) immune globulin. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Human Rho(D) immune globulin. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Human Rho(D) immune globulin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Human Rho(D) immune globulin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Human Rho(D) immune globulin. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Human Rho(D) immune globulin. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Human Rho(D) immune globulin. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Human Rho(D) immune globulin. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Human Rho(D) immune globulin. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Human Rho(D) immune globulin. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Human Rho(D) immune globulin. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Human Rho(D) immune globulin. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Human Rho(D) immune globulin. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Human Rho(D) immune globulin. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Human Rho(D) immune globulin. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Human Rho(D) immune globulin. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Human Rho(D) immune globulin. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Human Rho(D) immune globulin. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Human Rho(D) immune globulin. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Human Rho(D) immune globulin. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Human Rho(D) immune globulin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Human Rho(D) immune globulin. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Human Rho(D) immune globulin. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Human Rho(D) immune globulin. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Human Rho(D) immune globulin. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Human Rho(D) immune globulin. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Human Rho(D) immune globulin. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Human Rho(D) immune globulin. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Human Rho(D) immune globulin. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Human Rho(D) immune globulin. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Human Rho(D) immune globulin. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Human Rho(D) immune globulin. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Human Rho(D) immune globulin. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Human Rho(D) immune globulin. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Human Rho(D) immune globulin. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Human Rho(D) immune globulin. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human Rho(D) immune globulin. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Human Rho(D) immune globulin. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Human Rho(D) immune globulin. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Human Rho(D) immune globulin. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Human Rho(D) immune globulin. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Human Rho(D) immune globulin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Human Rho(D) immune globulin. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Human Rho(D) immune globulin. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Human Rho(D) immune globulin. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Human Rho(D) immune globulin. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Human Rho(D) immune globulin. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Human Rho(D) immune globulin. |